Scarneo, Scott A.
Eibschutz, Liesl S.
Bendele, Phillip J.
Yang, Kelly W.
Totzke, Juliane
Hughes, Philip
Fox, David A.
Haystead, Timothy A. J.
Funding for this research was provided by:
National Institute of General Medical Sciences (5T32GM007105-44)
Article History
Received: 29 March 2019
Accepted: 28 November 2019
First Online: 17 December 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: CIA RA and SS study performed by Bolder BioPATH was paid for by EydisBio Inc. TAH and PH are both part owners of EydisBio (Durham NC). Additionally, a patent has been issued (US10,207,998) for takinib, filed by TAH and PH. All other authors declare that they have no competing interests.